// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Should we abandon the APTT for monitoring the anticoagulant effect of unfractionated heparin?

D Jayakody Arachchillage - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Heparin

Anticoagulation outreach service

NMD McQuaid - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Warfarin

Presenting ADAMTS13 antibody and antigen levels correlate with clinical course and prognosis in immune‐mediated thrombotic thrombocytopenic purpura

F Alwan - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

A novel thrombomodulin gene variant leading to hyperthrombomodulinaemia and a hereditary bleeding disorder

A-L Latif - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Thrombomodulin alfa

Fever to needle time audit in patients with neutropenic sepsisDivision of Haemato‐oncology, St Bartholomew's Hospital

R Borrill - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Piperacillin/tazobactam

Elderly acute myeloid leukaemia (AML): treatment patterns, trial participation, inpatient resource use and outcomes: a single‐centre experience

AA Laing - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxycarbamide

Modifications in receptor affinity drives efficacy of CARCD123 T cells in AML

S Chitre - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Interleukin

Retrospective evaluation of antifungal prophylaxis for AML induction chemotherapy: the impact of switching from itraconazole to posaconazole

C Brown - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Itraconazole

Antifungal treatment costs in unselected acute myeloid leukemia patients – a Single Centre Experience

N Ramachandran - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Itraconazole

Incorporating patient and disease specific primers to established RQ PCR MRD monitoring helps in risk stratification in patients with T acute lymphoblastic leukaemia based on integrated reporting of diagnostic bone marrow samples

C Page - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

Management of patients with acute myeloid leukaemia (AML) presenting with hyperleucocytosis

L Mihailescu - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Hydroxycarbamide

FLAG‐ida for relapsed/refractory acute myeloid leukaemia: a single centre 5‐year study

C Agbuduwe - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

fludarabine tablet

An investigation into the role of S100A8 and S100A9 in acute myeloid leukaemia

S Chaudry - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Are anaemic patients referred for endoscopy truly iron deficient?

SP Hibbs - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Analysis of an online undergraduate haematology learning resource

A Jones - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CD8 T cell are involved in the pathogenesis of immune thrombocytopenia (ITP) and may be differentially modulated by the two thrombopoietin receptor agonists (TPO‐RAs)

AA Sayed - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Eltrombopag

Iron deficiency anaemia: quality improvement project

U Faruqi - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

How to set up a Social Media Medical Education website – the TeamHaem Experience

R Evans - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

A clinical audit of meropenem usage in a haemato‐oncology population since the introduction of the national antibiotic CQUIN

LMK Pannell - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Piperacillin/tazobactam

Transforming patient care: patient empowerment in clinical haematology

T Erblich - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved